BridgeBio Pharma financials
$65.97−0.96%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 |
|---|---|---|---|---|---|---|---|
| Revenue | $502.1M | $221.9M | $9.3M | $77.6M | $69.7M | $8.2M | $40.6M |
| Gross profit | $481.1M | $218.0M | $6.9M | $74.2M | $66.6M | $8.2M | $38.1M |
| Gross margin | 95.8% | 98.3% | 73.7% | 95.6% | 95.5% | 100.0% | 93.8% |
| Operating income | -$523.4M | -$593.0M | -$607.4M | -$512.2M | -$576.6M | -$474.5M | -$266.2M |
| Net income | -$724.9M | -$535.8M | -$643.2M | -$481.2M | -$562.5M | -$448.7M | -$260.6M |
| Net margin | −144.4% | −241.4% | −6913.9% | −619.7% | −806.9% | −5439.7% | −642.5% |
| Diluted EPS | $-3.78 | $-2.88 | $-3.95 | $-3.26 | $-3.90 | $-3.80 | $-2.48 |
| EBITDA | -$496.6M | -$571.3M | -$593.0M | -$461.7M | -$570.8M | -$473.0M | -$265.4M |
| Operating cash flow | -$445.9M | -$520.7M | -$527.7M | -$419.5M | -$497.9M | -$399.7M | -$253.6M |
| Free cash flow | -$447.0M | -$521.7M | -$529.0M | -$424.3M | -$511.2M | -$407.2M | -$256.2M |
| Diluted shares | 191.5M | 186.1M | 162.8M | 147.5M | 144.4M | 118.0M | 105.1M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $570.1M | $681.1M | $375.9M | $376.7M | $393.8M | $356.1M |
| Short-term investments | $17.4M | $0.00 | $58.9M | $95.2M | $442.9M | $251.0M |
| Total debt | $1.85B | $1.72B | $1.73B | $1.71B | $1.70B | $477.3M |
| Total assets | $936.0M | $919.3M | $546.4M | $623.0M | $1.01B | $703.6M |
| Total liabilities | $3.01B | $2.38B | $1.89B | $1.87B | $1.88B | $595.7M |
| Shareholders' equity | -$2.08B | -$1.46B | -$1.34B | -$1.24B | -$867.0M | $106.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology